You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
AstraZeneca
Moodys
McKinsey
Johnson and Johnson

Last Updated: February 16, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,807,364

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,807,364
Title:Angiogenesis pathway gene polymorphisms for therapy selection
Abstract: A method for determining whether a patient in need thereof will respond to anti-VEGF antibody based chemotherapy by screening a suitable cell or tissue sample isolated from the patient for at least one genomic polymorphism or genotype selected from (i) IL-8(-251); (ii) VEGF(936); or (iii) AM (3\' CA repeats), wherein the patient is suitably treated if the corresponding genotype is (i) (T/T) for IL-8(-251); (ii) (T/T or C/T) for VEGF(936); or (iii) at least one AM allele having 14 or more 3\' CA repeats.
Inventor(s): Lenz; Heinz-Josef (Altadena, CA)
Assignee: University of Southern California (Los Angeles, CA)
Application Number:11/681,695
Patent Claims:1. A method for determining whether a human ovarian cancer patient is more or less suitably treated by a therapy comprising administration of a bevacizumab antibody or an antibody that binds to the same epitope on VEGF as the bevacizumab, and cyclophosphamide comprising determining the genotype of IL-8 at position -251 present in a nucleic acid sample obtained from the patient, wherein the patient is more suitably treated if the patient's genotype is T/T at position -251 of IL-8 as compared to a patient having a genotype of A/A or A/T at position -251 of IL-8 or the patient is less suitably treated if the patient's genotype is A/A or A/T at position -251 of IL-8 as compared to a patient having a genotype of T/T at position -251 of IL-8.

2. A method for selecting a therapy comprising administration of a bevacizumab antibody or an antibody that binds to the same epitope on VEGF as the bevacizumab antibody, and cyclophosphamide for a human ovarian cancer patient comprising determining the genotype of IL-8 at position -251 present in a nucleic acid sample obtained from the patient wherein the therapy is selected if the patient's genotype is T/T at position -251 of IL-8 or the therapy is not selected if the patient's genotype is A/A or A/T at position -251 of IL-8.

3. A method for treating a human ovarian cancer patient selected for therapy based on presence of a genotype T/T at position -251 of IL-8 comprising administering an effective amount of a therapy comprising a bevacizumab antibody or an antibody that binds to the same epitope on VEGF as the bevacizumab antibody, and cyclophosphamide to the patient, wherein the patient was identified by a method comprising determining the genotype at position -251 of IL-8 present in a nucleic acid sample obtained from the patient.

4. The method of claim 1, wherein the patient is more suitably treated if the patient's genotype is T/T at position -251 of IL-8 as compared to a patient having a genotype of A/A or A/T at position -251 of IL-8.

5. The method of claim 1, wherein the patient is less suitably treated if the patient's genotype is A/A or A/T at position -251 of IL-8 as compared to a patient having a genotype of T/T at position -251 of IL-8.

6. The method of any one of claims 1, 4 and 5, wherein the nucleic acid sample is obtained from at least one of tumor tissue, normal tissue adjacent to the tumor, normal tissue corresponding to the tumor tissue or peripheral blood lymphocytes.

7. The method of claim 2, wherein the therapy is selected if the patient's genotype is T/T at position -251 of IL-8.

8. The method of claim 2, wherein the therapy is not selected if the patient's genotype is A/A or A/T at position -251 of IL-8.

9. The method of any one of claims 2, 7 and 8, wherein the nucleic acid sample is obtained from at least one of tumor tissue, normal tissue adjacent to the tumor, normal tissue corresponding to the tumor tissue or peripheral blood lymphocytes.

10. The method of claim 3, wherein the nucleic acid sample is obtained from at least one of tumor tissue, normal tissue adjacent to the tumor, normal tissue corresponding to the tumor tissue or peripheral blood lymphocytes.

11. The method of claim 1, wherein a patient that is more suitably treated by a therapy is a patient that has a higher response to the therapy.

12. The method of claim 1, wherein a patient that is less suitably treated by a therapy is a patient that has a lower response to the therapy.

13. The method of any one of claims 1, 2, 3, 4, 5, 7, 8 or 10 to 12, wherein the human ovarian cancer patient is a human refractory ovarian cancer patient.

14. The method of any one of claims 1, 2, 3, 4, 5, 7, 8 or 10 to 12, wherein the determining is by a method selected from the group PCR, sequencing, microarray, xMAP, invader assay, mass spectrometry or pyrosequencing.

15. The method of any one of claims 1, 2, 3, 4, 5, 7, 8, or 10 to 12, wherein the therapy comprises administration of a bevacizumab antibody and cyclophosphamide.

Details for Patent 7,807,364

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial University of Southern California (Los Angeles, CA) 2026-03-03 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial University of Southern California (Los Angeles, CA) 2026-03-03 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Johnson and Johnson
Express Scripts
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.